Background: Mitochondrial permeability transmembrane pore [mPTP] plays a vital role in alteration of the structure and function of mitochondria. Cyclophillin D is a mitochondrial protein that regulates mPTP function and a known drug target for therapeutic studies involving mitochondria. While aromatase inhibitor's role on mPTP has been previously studied, the role of anastrazole on mPTP is not completely elucidated.
INTRODUCTION
Mitochondrial disorders are a group of inherited disorders that arise when mitochondria fail to harvest sufficient energy for the body to function properly. Due to diverse genetic and clinical manifestations, the resultant complex phenotype often poses a diagnostic challenge. As a consequence of multiple steps involved in energy synthesis, amelioration of symptoms in these disorders is often difficult with a single point of action. No single compound till date is known to ameliorate the phenotype by acting on multiple steps that lead to mitochondrial dysfunction. This places greater emphasis on developing an alternative drug that can be considered for next generation mitochondrial modulating drugs.
Mitochondrial dysfunction ultimately results in increased matrix calcium. Calcium [Ca 2+ ] overload across the mitochondrial membrane results in massive production of oxygen derived free radicals. This as a consequence triggers the opening of the mega transition pore 1 , also known as mitochondrial permeability transition pore [mPTP] The depolarization of the mitochondrial membrane potential [Δψm] changes the dynamics of the ATP synthase leading to reduced production of ATP. This accelerates the cascade leading to energy depletion, secondary to cellular apoptosis [ Figure-1 ]. The distribution of Δψm thus could be considered as a potential prognostic factor which may assess the degree of tissue dysfunction or damage 5 .
Precise targeting of mitochondria with that of compounds has been a long cherished dream of drug development team, pharmacologists, and researchers. Cyclosporine A [CysA], a potent immunosuppressant, inhibit calcineurin signaling by forming the complex with cyclophillin A [CypA] [6] [7] [8] [9] , which is a known mPTP blocker. Several others mPTP blockers targeting cyclophillin D with less trivial fashion includes non-immune-suppressant derivative of CsA, N-methyl-Val-4-cyclosporin A [MeValCsA] 10 22 have been experimentally used to manipulate the ratio of mutant and wild type of mitochondrial DNA [mtDNA] in cell lines.
Figure-1: Cascades of mitochondrial dysfunctional events related to opening of mPTP pore:
The mPTP pore opening allows the release of molecules of size up to 1500 Daltons leads to the cascades of unfavorable events such as mitochondrial swelling, rupture of outer mitochondrial membrane leading to release of cytochrome c oxidase into the cytosol, loss of mitochondrial membrane potential, depletion of ATP levels.
Literature regarding the use of anastrozole as a selective and potent aromatase inhibitor suggests that it also controls mPTP opening 13 . Loredano Moro et al in their study demonstrated the role of anastrozole on modulation of mPTP pore in aromatase knockout [ArKO] mice.
We hypothesized that opening of the mPTP is most likely to be linked to multi-complex unit assembly rather that an isolated function and its modulation reflects the change in mitochondrial activities. Hence, we decided to perform the two tier study in which we first evaluated [molecular docking] the orientation of anastrozole to cyclophillin D [a key regulator of mPTP] and the physical movement [molecular dynamics] simulation of its active molecules during the interaction with cyclophillin D. We also intend to evaluate the effects of anastrozole [aromatase inhibitor] on modulation of mPTP and its effects on the mitochondrial cascade such as the Δψm, superoxide generation, ATP levels, caspase 3 activity and apoptosis in the PBMCs.
RESULTS
10 Patient's with mitochondrial disorders [Supplementary table S1 and figure S1 respectively] were recruited as per the E. morava et al. diagnostic criteria 23 . PBMCs were isolated for evaluating mitochondrial downstream function.
Docking and MD simulation analysis of molecular interaction between Cyclosporine A-Cyclophilin D and
Anastrozole -Cyclophilin D complexes:
Based on the active-site residues of Cyclophilin D obtained from the available literature 24 , protein-ligand molecular dockings were performed using AutoDock programs. To assess the accuracy and performance of docking procedure, the cyclosporine A docked structure was superimposed with its crystallized structure that resulted in a low RMSD value [~0.5 Å]. The protein-ligand interacting interface of both the complexes for cyclosporine A i.e. one obtained from in-silico docking procedure and other from the crystallographic studies were also checked for amino acid residues mediating the interactions. The conformations of in-silico docked and ligand-bound crystal structure were found to exhibit a conserved pattern of ligand binding in the active site. Several key residues involved in the binding pocket of cyclophillin D, including ARG55, PHE60, MET61, GLN63, GLY72, ASN102, ALA103 and HIS126 are shared at the level of inter-molecular interactions in both these complexes, indicating towards the reliability of the used docking protocol [ Figure 2 ]. Additionally, we have found that anastrozole was involved in the formation of a hydrogen bond with the protein at HIS54, which further stabilizes anastrozole in the binding pocket [ Figure 3A ]. For confirming the reliability of anastrozole binding mode inside the protein active site, stability of anastrozole within the protein cavity was compared with that of the known inhibitor cyclosporine A by performing the molecular dynamics simulations of both the complexes [as detailed in the material and methods section]. The resulting simulation trajectories when analyzed for backbone stability [in terms of RMSD] were found to fluctuate around 0.15nm for both the ligands [as shown by red and black lines in Figure 3B ]. For anastrozole the RMSD value range was 0.005 to 0.222nm, while for cyclosporine A it was 0.004 to 0.232nm. The trajectories of radius of gyration [Rg] with respect to time varied between 1.38 to 1.44 Å for anastrozole and between 1.39 to 1.43 Å for Cyclosporin A respectively [ Figure 3C ]. These values were showing increased fluctuations in the early phases of simulation, but a sustained plateau was obtained as the simulation proceeded, indicating the stability of conformation. For the comparative analysis, ligand binding conformations before and after the simulation was generated and studied in detail [ Figure 3D ]. ARG55, GLN63, GLY72, ALA101 and ASN102, ALA103, GLN111 and HIS126 formed strong hydrophobic contacts with the anastrozole. However, the nitrile group of anastrozole moved away from MET61 and ASN102, breaking the Hbond and making new hydrophobic interactions. Interestingly, this led the imidazole ring to move deeper into the binding pocket and form new hydrophobic contact with GLN111; an active site residue [ Figure 3D ]. Also, the Hbond between the HIS126 and anastrozole got much stronger [from 3.30 Å to 3.17 Å]. Anastrozole-cyclophillin D binding interface was also checked for the involvement of Arg55, a key pocket residue referred as catalytic arginine for the cyclophillin family 25 . The sustained interaction of anastrozole with Arg55, during the MD simulation represents the ability of ligand to facilitate reaction pathway.
Anastrozole's role in the inhibition of mPTP pore opening:
The mPTP opening in PBMCs was determined on the basis of change in green fluorescence intensity in the presence of and absence of H2O2 [ Figure 4 ]. The decrease in fluorescence using CoCl2 was greater in case group than the control group (p=0.006). Addition of H2O2 caused a further significant decrease in green fluorescence in the case group (p<0.001) indicating H2O2 induced opening of mPTP. While PBMCs exposed to H2O2 was treated with the drug at its nontoxic concentration [Supplementary figure S2 ], there was a significant increase in the green fluorescence in case group (p=0.001) [ Figure 4C ]. These results were more pronounced in the case group when compared to control group. While H2O2 induced early and late apoptosis in both case and control group after 6 hours of incubation, anastrozole significantly reduced the H2O2 induced apoptosis in both the groups (p=0.001). represents as mean ± SEM [n = 10 subjects; control and patient respectively] and comparisons were done for statistical significance using unpaired t-test (*p<0.05, **p<0.01, ### /***p<0.001).
Anastrozole modulated mitochondrial membrane potential:
CCCP significantly reduced MMP and the fluorescence of preloaded Cal-AM in healthy (p=0.001) and patient's PBMCs (p=0.001) in comparison to their untreated controls [ Figure 5A ]. However, treatment with anastrozole significantly reverted this CCCP-induced changes in control PBMCs (p=0.001) and in patient's PBMCs (p=0.001).
mitochondria. However, while this data was compared with healthy subjects, a significant difference was observed among anastrozole groups (p=0.002). However a significant difference in the function was observed in anastrozole's group when compared the same to the function of cyclosporine A. Data represents as mean ± SEM [n = 10 subjects; control and patient respectively] and comparisons were done as indicated using unpaired t-test (*p<0.05, **p<0.01 , ***p<0.001).
Anastrozole modulated superoxide generation:
Superoxide generation was higher in case group than the control group (p<0.001). However on treatment with, there was significant increase in superoxide in control group [ Figure 5B ]. Addition of anastrozole to CCCP treated mitochondria caused a significant reduction in the superoxide generation, more in the case group in comparison to the control group (p=0.002).
Anastrozole's role in calcium induced mitochondrial swelling:
The patient's mitochondria underwent rapid swelling in the presence of calcium, whereas anastrozole significantly inhibited calcium induced swelling [ Figure 5C ]. Cyclosporin A also significantly prevented swelling in patients' 
DISCUSSION
Mitochondriopathies accounts for majority of the common neurometabolic and neuromuscular disorders. No definitive therapy is available that directly modulates the function of mitochondria either by increasing the proportion of healthy mitochondria or by modulating the effects of mutated variants. The effects of various small molecules in mitochondrial disorders are currently being investigated in clinical and preclinical studies 26 . The current study highlights the three new observations: (1) Anastrozole is found to be relatively more stable on interaction with cyclophillin D with few conformational changes in comparison to the known Cyclosporine A-Cyclophillin D complex; (2) Mutation in mitochondrial governed genes leads to unfavorable modulation in mitochondrial activity and penultimately leads to cell death by an opening of mPTP; (3) Anastrozole modulates the mutant mitochondrial function by inhibiting mPTP opening and reducing the cell death in PBMCs of patients with mitochondrial disorder. Using literature survey, the binding pocket residues of the protein were identified.
Significant interactions of anastrozole at these binding pocket residues were obtained by the docking studies.
Identification of common interacting residues among the docked anastrozole and cyclosporine A bound crystal
structure of cyclophillin D showed that the binding potential of anastrozole is noteworthy. Also, H-bond integration of the anastrozole with His-126 might be playing a crucial role in stabilizing the protein-ligand complex [ Figure   3D ]. Further, binding affinity of the anastrozole was found to be relatively stable compared to its known inhibitor Figure 5C ] and the uncontrolled opening of the mPTP leading to cell death [ Figure 6B ]. The opening of mPTP occurred as a response to an apoptotic stimulus, resulting in the release of different apoptogenic molecules 27 . Several factors increased the sensitivity of conformity changes in mitochondria to eventually forcing the opening of mPTP, including increased ROS generation, depletion of ATP levels and depolarization of mitochondrial membrane potentials 28, 29 . In our study, we also observed the elevated mitochondrial superoxide production [ Figure 5B ], depolarized membrane [ Figure 5A ] and low ATP level [ Figure 6A ] in PBMCs of the patients. It was also reported that the loss of MMP and superoxide production during a stress condition, induces cell death 30 . Studies have also suggested that mutation in the mitochondrial genome affected the electron transport chain activity and thereby ATP production. Till date, no single FDA approved molecule is available for the treatment of mitochondrial disorders 31 . However, several drug targets were reported for these disorders 32, 33 including mitochondrial membrane protein known as cyclophillin-D, that regulates the mitochondrial transmembrane pore. Aromatase enzyme also regulates mPTP opening [34] [35] [36] . However, few reports showed that deficiency of aromatase enzyme inhibits the mPTP opening 13 . In the same study 13 , authors didn't observe any significant change in the membrane depolarization, ROS generation and ATP level depletion in the liver mitochondria of genetically knockout [aromatase] mice. However, in our study, we observed that anastrozole restored mitochondrial membrane potential [ Figure 5A ], reduces the superoxide level [ Figure 6B ] and cell death [ Figure 6B ], and this could be due to the temporary closing of mPTP by the drug. These results are also in line with the modulation capability of the known mPTP inhibitor cyclosporine A.
Anastrozole seems to be a promising agent in ameliorating the phenotype by regulating the activity across the mPTP pore. Larger functional studies including the levels of cytochrome c oxidase may give insight into mechanistic modulation of the mPTP pore carried out by this agent. Clinical trials with this molecule may therefore provide insight into its advantages, selectivity and dosage regulation.
MATERIALS AND METHODS
The study carried out with the necessary approval from the Maulana azad medical college affiliated Institutional Ethical Committee (MAMC-IEC) board and complies all necessary steps with the Declaration of Helsinki. The cross-sectional study adhered to the Ethical Principles for Medical Research Involving Human Subjects, World Medical Association Declaration of Helsinki. A convenient patient sample size of 10 was taken due to difficulty in diagnosing the disorder into the consideration along with 10 healthy control samples. Informed consent was obtained from all subjects.
Isolation of PBMCs:
Ten healthy control [age-sex matched] and ten patients with mitochondrial disorders were selected by using 
Drug toxicity assay:
The appropriate dosage selection of anastrozole was identified by using the methylthiazol tetrazolium [MTT] assay on human embryonic kidney cells [HEKs]. HEKs were treated with different concentrations of the drug, in RPMI 1640 media for 6 hours in CO2 incubator. After removing the media, the obtained formazan crystals were stabilized by the addition of dimethyl sulfoxide [DMSO] . Absorbance was measured [570 nm] using a spectrophotometer and a plate reader, and growth inhibition was calculated.
DOCKING AND MOLECULAR SIMULATION STUDY

Preparation of cyclophillin D and ligand for molecular docking:
Three-dimensional crystal structure of Cyclophilin D [PDB ID: 2BIT] resolved at 1.7Å 37 was obtained from protein data bank in order to use it as a docking template. Cyclosporin A, a known Cyclophilin D receptor antagonist was selected as the positive and/or reference compound to compare it with target compound anastrozole. These two compounds were prepared for molecular docking, processed and minimized with the help of Open Babel version 2.4.1 38 .
Parameter optimization and molecular docking:
AutoDock version 4.2 was used to perform the docking studies mainly due to its processing speed and superior ability for binding mode prediction 39 . First of all, information about the binding pocket of Cyclosporine A in Cyclophilin D was obtained from available literature 24 . Optimal grid structure was selected and coordinates covering the whole binding site of the Cyclophilin D were chosen for further studies. The parameters adopted were, Ligplot+, a graphical system that utilizes 3D coordinates to generate the interaction maps was used to visualize the interaction present in protein-ligand complex 47 . Molecular graphics were generated using PyMOL 48 . 
CASCADES OF EVENTS
Mitochondrial superoxide generation assay:
To determine mitochondrial superoxide production in healthy and patients PBMCs, dihydroxy ethidium staining was performed. Isolated PBMCs were treated with the drug for ten minutes and then incubated with H2O2. After washing, cells were treated with 1µM of dihydroethidium and immediately analyzed using BD Accuri C6 software.
Mitochondrial membrane potentials assay:
PBMCs were incubated with the drug for 10 minutes in a CO2 incubator and then treated with H2O2 and/or protonophore-m-chlorophenylhydrazone [CCCP] for another 30 minutes. Cells were washed twice and stained with 10 nM Rhodamine 123 [Rh123] and analyzed using BD Accuri C6 software.
ATP assay:
The cellular total ATP level quantification was done after completion of treatment using a commercially available chemilluminescence assay kit [Sigma Aldrich, USA]. Protocol was followed according to manufacturer instructions.
Annexin-V/PI and caspase-3 assays:
Cell death was quantified using Annexin-V/PI kit and protocol was followed according to manufacturer's instructions. Briefly, after completion of treatment, cells were subjected to a binding buffer containing annexin V and propidium iodide and incubated at room temperature for 15 minutes and acquired by flowcytometry. Similarly, cleaved caspase-3 levels in isolated healthy and patient PBMCs was measured by following the kit manufacture's instruction [Caspase-3 assay kit, Abcam, ab39383].
Statistical analysis:
All the results are presented as mean ± standard error of the mean [SEM]. All statistical analysis were performed using GraphPad Prism from GraphPad Software [v5.0, La Jolla, CA, USA]. One way ANOVA repeated measure followed by boneferoni post-test were used for multiple comparisons. Student's t-test was used for single comparison of analytes. p-value less than 0.05 were considered statistically significant.
